Concepts (130)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Agents | 6 | 2018 | 1672 | 0.560 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2013 | 23 | 0.420 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2013 | 35 | 0.420 |
Why?
|
| Receptor, Notch1 | 3 | 2018 | 66 | 0.410 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2013 | 262 | 0.380 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2013 | 353 | 0.350 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 617 | 0.330 |
Why?
|
| Colorectal Neoplasms | 3 | 2018 | 560 | 0.260 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2018 | 522 | 0.190 |
Why?
|
| Cancer Care Facilities | 1 | 2020 | 30 | 0.180 |
Why?
|
| Pancreatic Neoplasms | 2 | 2016 | 673 | 0.140 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 99 | 0.140 |
Why?
|
| Ephrin-B2 | 1 | 2016 | 9 | 0.140 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2016 | 23 | 0.140 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2018 | 876 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2018 | 714 | 0.140 |
Why?
|
| Salvage Therapy | 1 | 2018 | 193 | 0.140 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2016 | 55 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 3 | 2018 | 1011 | 0.130 |
Why?
|
| Pyrazoles | 1 | 2018 | 303 | 0.130 |
Why?
|
| Pyrimidines | 1 | 2018 | 374 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2014 | 28 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2014 | 66 | 0.120 |
Why?
|
| Anilides | 1 | 2014 | 48 | 0.120 |
Why?
|
| Biomarkers, Tumor | 3 | 2016 | 1429 | 0.120 |
Why?
|
| Neoplasms | 3 | 2018 | 2772 | 0.110 |
Why?
|
| Up-Regulation | 1 | 2016 | 864 | 0.110 |
Why?
|
| Gene Dosage | 1 | 2015 | 441 | 0.110 |
Why?
|
| Pyridines | 1 | 2014 | 224 | 0.110 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2013 | 55 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2013 | 58 | 0.100 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2012 | 8 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2013 | 79 | 0.100 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2012 | 39 | 0.100 |
Why?
|
| Pyrimidinones | 1 | 2012 | 40 | 0.100 |
Why?
|
| Bone Neoplasms | 1 | 2016 | 427 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 1115 | 0.100 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 481 | 0.100 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2016 | 542 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 651 | 0.090 |
Why?
|
| Pyridones | 1 | 2012 | 112 | 0.090 |
Why?
|
| Mutation | 2 | 2016 | 5770 | 0.090 |
Why?
|
| Mice, Nude | 3 | 2018 | 692 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2015 | 939 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2013 | 714 | 0.080 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 2481 | 0.080 |
Why?
|
| Neoplasm Metastasis | 3 | 2020 | 650 | 0.080 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2009 | 148 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 1308 | 0.070 |
Why?
|
| Prognosis | 4 | 2018 | 4508 | 0.060 |
Why?
|
| Maximum Tolerated Dose | 2 | 2018 | 157 | 0.060 |
Why?
|
| Mucin-1 | 1 | 2004 | 33 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2018 | 207 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 2047 | 0.060 |
Why?
|
| Middle Aged | 7 | 2020 | 26002 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2013 | 1515 | 0.060 |
Why?
|
| Aged | 6 | 2020 | 19088 | 0.050 |
Why?
|
| Mice | 6 | 2018 | 17486 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 1231 | 0.050 |
Why?
|
| Male | 8 | 2018 | 60083 | 0.050 |
Why?
|
| Carcinoma | 1 | 2004 | 278 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 352 | 0.050 |
Why?
|
| Female | 10 | 2020 | 65494 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 860 | 0.050 |
Why?
|
| Animals | 7 | 2018 | 33713 | 0.050 |
Why?
|
| Humans | 11 | 2020 | 123182 | 0.050 |
Why?
|
| Colorado | 1 | 2020 | 22 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2020 | 57 | 0.040 |
Why?
|
| Adult | 6 | 2020 | 29065 | 0.040 |
Why?
|
| Apoptosis | 2 | 2018 | 1781 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2016 | 1470 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2018 | 3270 | 0.040 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2018 | 6 | 0.040 |
Why?
|
| M Phase Cell Cycle Checkpoints | 1 | 2018 | 5 | 0.040 |
Why?
|
| Time Factors | 2 | 2020 | 6211 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2018 | 382 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2020 | 3334 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 6376 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2018 | 612 | 0.030 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2015 | 38 | 0.030 |
Why?
|
| Jagged-1 Protein | 1 | 2015 | 51 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2014 | 53 | 0.030 |
Why?
|
| Risk Factors | 2 | 2020 | 10021 | 0.030 |
Why?
|
| Transfection | 1 | 2016 | 1067 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 793 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1681 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2014 | 74 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2016 | 739 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2015 | 327 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 1004 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2015 | 281 | 0.030 |
Why?
|
| Gene Duplication | 1 | 2015 | 358 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 1996 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 240 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 1305 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 1682 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2015 | 4493 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2014 | 340 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 2012 | 141 | 0.030 |
Why?
|
| Half-Life | 1 | 2012 | 156 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 4269 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 490 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 313 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2018 | 2306 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2012 | 158 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 2114 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2020 | 16022 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 730 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2012 | 671 | 0.020 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2009 | 28 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 1681 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2009 | 68 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 1870 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 5050 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 4707 | 0.020 |
Why?
|
| Pancreatectomy | 1 | 2009 | 136 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2016 | 12129 | 0.020 |
Why?
|
| Biopsy | 1 | 2012 | 1239 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 182 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2009 | 601 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2015 | 1530 | 0.020 |
Why?
|
| Phenotype | 1 | 2016 | 4227 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 3083 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 1240 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2009 | 1213 | 0.020 |
Why?
|
| United States | 2 | 2012 | 10632 | 0.020 |
Why?
|
| Antibody Formation | 1 | 2004 | 256 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2004 | 203 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 1262 | 0.010 |
Why?
|
| Young Adult | 1 | 2012 | 8885 | 0.010 |
Why?
|